Celcuity Inc. (NasdaqCM: CELC)
Health Care · Biotechnology · US
$94.14
+0.65% today · +78.4% 1Y
Celcuity Inc. (NasdaqCM: CELC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.58B and employs 155 people.
Over the last twelve months the share price has gained 78.4%, trading between 44.42 and 151.02.
Tweenvest scores Celcuity Inc. across four factors: quality 13/100. Its strongest factor is quality.
CELC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.58B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.32
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- $151.02
- 52-week low
- $44.42
- Avg volume (3M)
- —
- Shares outstanding
- 48.93M
- Employees
- 155
- Next earnings
- —
About Celcuity Inc.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
- ISIN
- US15102K1007
- Founded
- 2011
- Listed since
- Sep 19, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.85 | +0.34% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.74 | +0.09% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.56 | +0.30% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $842.16 | +0.97% |
| argenx SEENXTBR: ARGX | $65.85B | €880.20 | -2.42% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.47 | -1.10% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.